vs
Strata Critical Medical, Inc.（SRTA）与Talkspace, Inc.（TALK）财务数据对比。点击上方公司名可切换其他公司
Talkspace, Inc.的季度营收约是Strata Critical Medical, Inc.的2.8倍（$63.0M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 29.3%）。过去两年Talkspace, Inc.的营收复合增速更高（17.8% vs -33.6%）
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
Talkspace, Inc.是一家提供线上与移动端心理咨询服务的美国企业，由奥伦·弗兰克与罗尼·弗兰克创立于2012年，总部位于纽约。公司依托网页与移动端平台，帮助用户对接具备执业资质的心理咨询师与精神科医师，支持文字、音频、视频消息沟通，部分场景还可提供实时视频咨询服务。
SRTA vs TALK — 直观对比
营收规模更大
TALK
是对方的2.8倍
$22.7M
营收增速更快
SRTA
高出331.9%
29.3%
两年增速更快
TALK
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $22.7M | $63.0M |
| 净利润 | — | $4.8M |
| 毛利率 | -0.9% | — |
| 营业利润率 | -18.4% | 6.1% |
| 净利率 | — | 7.6% |
| 营收同比 | 361.2% | 29.3% |
| 净利润同比 | — | 292.5% |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SRTATALK
| Q4 25 | $22.7M | $63.0M | ||
| Q3 25 | $49.3M | $59.4M | ||
| Q2 25 | $70.8M | $54.3M | ||
| Q1 25 | $54.3M | $52.2M | ||
| Q4 24 | $-8.7M | $48.7M | ||
| Q3 24 | $36.1M | $47.4M | ||
| Q2 24 | $67.9M | $46.1M | ||
| Q1 24 | $51.5M | $45.4M |
净利润SRTATALK
| Q4 25 | — | $4.8M | ||
| Q3 25 | $57.4M | $3.3M | ||
| Q2 25 | $-3.7M | $-541.0K | ||
| Q1 25 | $-3.5M | $318.0K | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-2.0M | $1.9M | ||
| Q2 24 | $-11.3M | $-474.0K | ||
| Q1 24 | $-4.2M | $-1.5M |
毛利率SRTATALK
| Q4 25 | -0.9% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 22.1% | 44.6% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | 20.8% | 45.6% | ||
| Q2 24 | 24.1% | 45.5% | ||
| Q1 24 | 19.7% | 47.8% |
营业利润率SRTATALK
| Q4 25 | -18.4% | 6.1% | ||
| Q3 25 | -11.4% | 3.7% | ||
| Q2 25 | -7.0% | -3.3% | ||
| Q1 25 | -14.0% | -2.1% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | -19.7% | 0.2% | ||
| Q2 24 | -17.9% | -7.6% | ||
| Q1 24 | -19.2% | -3.7% |
净利率SRTATALK
| Q4 25 | — | 7.6% | ||
| Q3 25 | 116.5% | 5.5% | ||
| Q2 25 | -5.3% | -1.0% | ||
| Q1 25 | -6.4% | 0.6% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | -5.4% | 4.0% | ||
| Q2 24 | -16.7% | -1.0% | ||
| Q1 24 | -8.2% | -3.2% |
每股收益（稀释后）SRTATALK
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $0.70 | $0.02 | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.11 | $0.01 | ||
| Q3 24 | $-0.03 | $0.01 | ||
| Q2 24 | $-0.15 | $0.00 | ||
| Q1 24 | $-0.06 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.0M | $37.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $279.1M | $117.0M |
| 总资产 | $325.5M | $134.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SRTATALK
| Q4 25 | $31.0M | $37.4M | ||
| Q3 25 | $22.8M | $39.5M | ||
| Q2 25 | $58.8M | $54.3M | ||
| Q1 25 | $34.8M | $60.1M | ||
| Q4 24 | $18.4M | $76.7M | ||
| Q3 24 | $20.0M | $119.0M | ||
| Q2 24 | $26.3M | $114.9M | ||
| Q1 24 | $36.8M | $120.3M |
股东权益SRTATALK
| Q4 25 | $279.1M | $117.0M | ||
| Q3 25 | $283.0M | $109.1M | ||
| Q2 25 | $223.1M | $112.9M | ||
| Q1 25 | $219.7M | $113.4M | ||
| Q4 24 | $221.9M | $117.4M | ||
| Q3 24 | $233.5M | $117.6M | ||
| Q2 24 | $229.4M | $114.0M | ||
| Q1 24 | $236.6M | $119.6M |
总资产SRTATALK
| Q4 25 | $325.5M | $134.9M | ||
| Q3 25 | $335.1M | $129.1M | ||
| Q2 25 | $257.9M | $132.8M | ||
| Q1 25 | $250.6M | $134.2M | ||
| Q4 24 | $256.7M | $138.7M | ||
| Q3 24 | $282.9M | $138.2M | ||
| Q2 24 | $280.3M | $133.8M | ||
| Q1 24 | $282.8M | $138.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.3M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $-10.2M | — |
| 自由现金流率自由现金流/营收 | -44.7% | — |
| 资本支出强度资本支出/营收 | 8.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $-58.5M | — |
8季度趋势，按日历期对齐
经营现金流SRTATALK
| Q4 25 | $-8.3M | $5.4M | ||
| Q3 25 | $-37.3M | $4.7M | ||
| Q2 25 | $-3.1M | $-351.0K | ||
| Q1 25 | $-246.0K | $-1.2M | ||
| Q4 24 | $-1.8M | $3.7M | ||
| Q3 24 | $6.4M | $6.2M | ||
| Q2 24 | $8.4M | $4.8M | ||
| Q1 24 | $-15.6M | $-3.4M |
自由现金流SRTATALK
| Q4 25 | $-10.2M | — | ||
| Q3 25 | $-40.1M | — | ||
| Q2 25 | $-5.4M | — | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $-6.3M | — | ||
| Q3 24 | $-3.0M | — | ||
| Q2 24 | $-7.7M | $4.5M | ||
| Q1 24 | $-16.4M | $-3.8M |
自由现金流率SRTATALK
| Q4 25 | -44.7% | — | ||
| Q3 25 | -81.4% | — | ||
| Q2 25 | -7.6% | — | ||
| Q1 25 | -5.3% | — | ||
| Q4 24 | 72.7% | — | ||
| Q3 24 | -8.2% | — | ||
| Q2 24 | -11.4% | 9.7% | ||
| Q1 24 | -31.8% | -8.3% |
资本支出强度SRTATALK
| Q4 25 | 8.1% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -52.6% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 23.8% | 0.7% | ||
| Q1 24 | 1.6% | 0.8% |
现金转化率SRTATALK
| Q4 25 | — | 1.13× | ||
| Q3 25 | -0.65× | 1.46× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3.90× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
TALK
| Payor Revenue | $47.7M | 76% |
| Dte Revenue | $11.6M | 18% |
| Consumer | $3.7M | 6% |
